POPULARITY
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/KAQ865. CME/MOC credit will be available until May 27, 2026.From Innovation to Implementation: Unlocking the Full Potential of Antibody-Drug Conjugates in Solid Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.
Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases. Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate." "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell. And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell. So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Listen to the podcast here
Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases. Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate." "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell. And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell. So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Download the transcript here
Send us a textPart 2 of our discussion on bladder cancer with Professor Rob Jones.We have new drug classes in Bladder cancer !!We look at Erdafitinib which is coming in the post Immunotherapy space to NHS England.We also look ahead to Antibody Drug Conjugates - in particular Enfortumab Vedotin - with EV 302 trial results and what access to this means for the UK bladder community. These are exciting times and we discuss potential side effects of these classes of drugs and how we intend to use them.Enjoy
Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient's perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx. “[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I'm not just a number, I'm a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett Nancy Mallett Patient Advocate Resources: FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8 Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962 Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ Funder Statement This program is supported by AbbVie.
Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.
Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC) — Dr Borges (9:56) Targeting the PTEN/PI3K/AKT Pathway in HR-Positive mBC — Dr Burstein (35:20) Role of Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive mBC — Dr O'Shaughnessy (1:03:07) Antibody-Drug Conjugates for HR-Positive mBC — Dr Bardia (1:36:12) CME information and select publications
Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.
CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.=
Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Shilpa Gupta, MD New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.
Join the experts for all you need to know about antibody-drug conjugates (ADCs) in breast cancer. Credit available for this activity expires: 2/28/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002233?ecd=bdc_podcast_libsyn_mscpedu
Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Disease (2:34) Adjuvant and Neoadjuvant Therapy (22:31) EGFR Exon 20 Insertion Mutations (34:21) Antibody-Drug Conjugates (42:45) CME information and select publications
In today's episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas. In our exclusive interview, Dr Gerber discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), focusing on findings from key clinical trials. He highlighted results from the phase 3 TROPION-Lung01 trial (NCT04656652), which demonstrated a modest improvement in progression-free survival with datopotamab deruxtecan-dlnk (Datroway), a TROP2-directed ADC, compared with docetaxel in patients with previously treated advanced NSCLC. He also emphasized the toxicity profile of TROP2-directed ADCs, particularly gastrointestinal toxicities and myelosuppression. Dr Gerber also reviewed the phase 2 HERTHENA-Lung01 trial (NCT04619004) evaluating patritumab deruxtecan in patients with EGFR-mutant NSCLC and the phase 2 DESTINY-Lung02 trial (NCT04644237) assessing fam-trastuzumab deruxtecan-nxki (Enhertu) in those with HER2-mutant NSCLC. Dr Gerber reflected on the shared DXd payload of these ADCs, highlighting its implications for toxicity and efficacy, as well as open questions regarding treatment sequencing and resistance mechanisms.
Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Patient Videos and Clinical Investigator Survey (3:26) San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03) Patient Videos and Clinical Investigator Survey (43:27) SABCS Report — Abstracts of Interest (55:56) Patient Videos and Clinical Investigator Survey (56:27) CME information and select publications
In this episode of Onc Now, Jonathan welcomes Ahmad Awada, Head of the Oncology Department at Chirec Cancer Institute in Brussels and Editor in Chief of EMJ Oncology. Together they discuss groundbreaking developments in cancer care, the promise of targeted therapies, and the importance of global collaboration in oncology. Timestamps: (00:00)-Introduction (01:20)-Reflecting on ESMO 2024 (07:37)-Looking ahead to ESMO 2025 (10:04)-Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates (13:24)-New cytotoxics and molecular targeted therapies for solid tumours (16:30)-Surgery of primary tumour in de novo metastatic breast cancer (19:29)-Improving survival in cancer patients (22:47)-Managing the risk of thromboembolism (24:43)-Exciting advancements on the horizon (29:38)-Wishes for oncology
Featuring perspectives from Dr Heather Wakelee, including the following topics: Introduction (0:00) Cases: A man in his late 50s with metastatic carcinoma of the lung, no actionable genomic alteration (AGA), PD-L1-negative, and a man in his early 60s with metastatic squamous cell carcinoma of the lung, PD-L1-negative — Brian P Mulherin, MD and Taral Patel, MD (8:08) Case: A man in his late 60s presenting with metastatic adenocarcinoma of the lung, multiple bone metastases, no AGA; PD-L1 20%; enrolled on ECOG-EA5163 — Priya Rudolph, MD, PhD (21:45) Current and Emerging Immunotherapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (mNSCLC) (30:55) Case: An African American man in his early 60s with 6.2-cm squamous cell carcinoma of right upper lung receives neoadjuvant treatment as per CheckMate 816 — Dr Rudolph (39:16) Case: A man in his late 60s with pT2aN0 invasive adenocarcinoma of the right lower lung, no AGA; PD-L1 5% — Zanetta S Lamar, MD (44:57) Antibody-Drug Conjugates and Other Management Approaches for mNSCLC without AGAs (48:51) Case: A woman in her early 60s diagnosed in 2014 with metastatic adenocarcinoma of the lung treated on ECOG 5508 (carboplatin/paclitaxel/bevacizumab) receives nivolumab on disease progression — Dr Rudolph (56:35) CME information and select publications
In this episode of the Patient from Hell podcast, we speak with Dr. Milana Dolezal, an oncologist from Stanford University, and learn about cutting-edge advancements in cancer treatments, particularly antibody-drug conjugates (ADCs) and precision medicine. Dr. Dolezal shares her journey from childhood inspiration to a career in oncology, the evolution of cancer therapies, and how recent innovations are transforming metastatic cancer care. The conversation also delves into the intricacies of cancer biology, the impact of emerging treatments on quality of life, and the hope for a future where therapies are tailored not only to the disease but also to managing side effects effectively. Key Highlights: 1. Oncology Advancements: Dr. Dolezal explains the development of antibody-drug conjugates (ADCs) that deliver chemotherapy directly to cancer cells, reducing side effects compared to traditional treatments. 2.Cancer's Complexity: Using vivid analogies, Dr. Dolezal illustrates how cancer evolves to resist treatments, comparing it to navigating New York's subway system. 3. Managing Side Effects: Dr. Dolezal emphasizes a "go low and go slow" approach in administering treatments to minimize side effects, tailoring doses to individual patients' needs to balance efficacy with maintaining quality of life. About our guest: Dr. Dolezal is a board-certified hematologist-oncologist with Stanford Medicine Cancer Center in Emeryville and a clinical associate professor in the Stanford School of Medicine, Division of Oncology. She strives to work with patients to develop care plans that are comprehensive and personalized to achieve the best possible outcomes and quality of life. She also has extensive experience in research and drug development. She previously held positions as a clinical scientist, assistant medical director, and associate medical director in the BioOncology Therapeutics unit of the biotechnology company Genentech. She has conducted clinical research into fertility preservation in patients with breast cancer, advanced treatments for triple-negative breast cancer, and patients' adherence to anti-cancer therapy. She has co-authored articles on her research findings that appeared in the Journal of Clinical Oncology, Cancer, and other peer-reviewed publications. She also co-authored the chapter “Progression from Hormone-Dependent to Hormone-Independent Breast Cancer” in the textbook Hormones, Genes and Cancer published by Oxford University Press. Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics: Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00) Selection and Sequencing of Antibody-Drug Conjugates (5:09) Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39) Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04) Discussing Palliative and End-of-Life Care (32:40) PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53) The “Art of Oncology” — Building Trust with Patients and Family Members (45:05) Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44) Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53) CME information and select publications
Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD). Episode Highlights: • Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice. • Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care. • Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management. This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs. Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs, and where he sees ADCs heading in the future. LINKS: Bionavigen NEXT Oncology
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
October 15, 2024 | In this month's episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more. LINKS:BionavigenImmunoGen
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CES865. CME credit will be available until October 9, 2025.Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CES865. CME credit will be available until October 9, 2025.Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CES865. CME credit will be available until October 9, 2025.Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CES865. CME credit will be available until October 9, 2025.Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.
In this episode of Life Science Success, we sit down with Paul Jaminet, Ph.D., founder and CEO of Angiex, Inc., to explore his groundbreaking work in developing Nuclear-Delivered Antibody-Drug Conjugates™ for cancer therapy. Paul shares his unique career journey from astrophysics to biotech, insights into leading innovative projects, and the challenges and triumphs of pushing the boundaries in cancer treatment. Don't miss this inspiring conversation with a visionary leader in the life sciences.
Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics: Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00) Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42) Other Targets for ADC Therapy in mBC — Prof Schmid (44:59) CME information and select publications
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/ADCsmBC)
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Case: A woman in her late 40s who received treatment for triple-negative breast cancer develops lung metastases 2 years later (0:00) Clinical trials investigating TROP2-targeting antibody-drug conjugates (13:28) Identifying and targeting HER2 in HER2 low-expressing disease (21:17) Case: A woman in her early 50s who received treatment for Stage I breast cancer later develops multiple lesions similar to the original cancer (29:00) Thresholds of HER2 expression and the efficacy of trastuzumab deruxtecan (T-DXd) (34:01) Case: A woman in her late 50s receiving T-DXd for HER2-low metastatic breast cancer develops asymptomatic ground glass infiltrates in the lung (39:19) Novel ADC strategies under investigation (48:22) CME information and select publications
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayADCsmBC24).
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates for MM — Jesús G Berdeja, MD CME information and select publications
Featuring an interview with Dr Jonathan W Goldman, including the following topics: Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05) Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16) Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29) CME information and select publications
Featuring perspectives from Dr Rebecca S Heist, Dr Luis Paz-Ares and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations — Dr Paz-Ares (1:28) Emerging Role of TROP2-Targeted ADCs for NSCLC — Dr Sands (23:12) Other Promising Targets for ADCs for Lung Cancer — Dr Heist (39:07) CME information and select publications